Key Takeaways TEM's Q3 revenue rose 84.7% to $334.2M as genomics testing demand and data services drove growth.Higher volumes, better pricing, and sales efficiency helped gross profit jump 98$209.9M.Improved reimbursement and FDA pathways support visibility into pricing and long-term leverage.Tempus AI (TEM) posted another breakout quarter as diagnostics volumes and pricing improved while data partnerships extended visibility. Execution on mix, reimbursement and bookings sets a clearer path to operatin ...